Investing in R&D to drive high-value pipeline delivery

Annual Report 2025
Case study

Our purpose in action Hikma is committed to building a differentiated pipeline of complex products. Under a newly unified global R&D organisation, we have consolidated research capabilities into a single Group structure with three hubs in Ohio, US, Jordan and Croatia, specialising in Respiratory; nasals, semi-solids and liquids (RNSSL); Solid Orals and Injectables. This reorganisation optimises resources, strengthens capabilities, standardises product selection across technical platforms, and accelerates time-to-market, supporting strategic growth priorities for our Injectables, Branded and Hikma Rx businesses.

Complex products creating significant market opportunities.

Our pipeline focuses on both simple and technically complex, differentiated products addressing unmet medical needs, for example: We are developing a single-dose epinephrine nasal spray for emergency anaphylaxis treatment. With the US epinephrine auto-injector market forecast to be valued at approximately $1.2 billion by 2032 , this innovative nasal alternative offers substantial benefit through improved ease of administration and patient compliance.

Tyzavan^® our reformulated vancomycin ready-to-use injectable medicine is another example of how we are adding complexity to our product portfolio. This patent-protected, ready-to-use, room temperature stable bag addresses critical hospital needs for treating serious infections including septicaemia.

“Our new unified R&D organisation optimises our resources, strengthens our capabilities, standardises the product selection process across our technical platforms, accelerates time-to-market and supports our strategic growth priorities.”

Hafrun Fridriksdottir
President, US and Global Head of R&D